ArticleAdvanced healthcare materials2026
Metallofullerenol Sc
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protective mechanisms and therapeutic promise of nanomaterials in radiation-induced diseases.International journal of pharmaceutics: X · 2026Review
- Structure-Dependent Antioxidant Activity of Ibogalogs: Impact of Methoxy Group Position on the Protective Activity in Model and Synaptosomal Lipid Membranes.ACS chemical neuroscience · 2026Article
- Effect of Fullerenol CNanomaterials (Basel, Switzerland) · 2026Article
- Metallofullerenol ScAdvanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metallofullerenols (MFs), functionalized endohedral fullerenes, exhibit unique activity by integrating atomic, molecular, and supramolecular levels of matter organization. The antioxidant properties of MFs constitute a novel technology, utilizing these nanocompounds for radioprotection. This integration of nanotechnology with radiological protection may contribute to revolutionary solutions in nuclear safety. Preclinical studies demonstrate low toxicity of MFs and high therapeutic value as redox mediators. In this study, the interaction of the metallofullerenol Sc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.